Literature DB >> 1921244

Remarkable improvement of neuropsychiatric symptoms in HIV-infected patients after AZT therapy.

M Hollweg1, R R Riedel, F D Goebel, U Schick, D Naber.   

Abstract

Treatment of neuropsychiatric symptoms with AZT (Azidothymidine) seems to be effective in many AIDS patients. In earlier studies, 204 of 525 patients treated with AZT showed neuropsychiatric improvement. In this presentation, two patients with affective disorder and dementia are described. Both patients showed remarkable improvement of their severe psychiatric symptoms after AZT. The authors recommend treatment of AIDS-associated dementia and psychoorganic symptoms with AZT.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1921244     DOI： 10.1007/bf01647415

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  12 in total

Review 1.  [Azidothymidine and the nervous system].

Authors:  R R Riedel; L Bader; L Gürtler; J Eberle; W Günther; D Naber
Journal:  Fortschr Med       Date:  1991-05-10

2.  From the Food and Drug Administration. Update on zidovudine.

Authors:  S L Nightingale
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

3.  Necrotising myopathy and zidovudine.

Authors: 
Journal:  Lancet       Date:  1988-05-07       Impact factor: 79.321

4.  Acute meningo-encephalitis on dose reduction of zidovudine.

Authors:  M Helbert; D Robinson; B Peddle; S Forster; A Kocsis; D Jeffries; A J Pinching
Journal:  Lancet       Date:  1988-06-04       Impact factor: 79.321

Review 5.  Neurologic manifestations of AIDS.

Authors:  J C McArthur
Journal:  Medicine (Baltimore)       Date:  1987-11       Impact factor: 1.889

6.  Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.

Authors:  F A Schmitt; J W Bigley; R McKinnis; P E Logue; R W Evans; J L Drucker
Journal:  N Engl J Med       Date:  1988-12-15       Impact factor: 91.245

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Authors:  A C Collier; S Bozzette; R W Coombs; D M Causey; D A Schoenfeld; S A Spector; C B Pettinelli; G Davies; D D Richman; J M Leedom
Journal:  N Engl J Med       Date:  1990-10-11       Impact factor: 91.245

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more
  2 in total

Review 1.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 2.  Human immunodeficiency virus type 1 infection of the brain.

Authors:  W J Atwood; J R Berger; R Kaderman; C S Tornatore; E O Major
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.